DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Safety and Tolerability Study of an Edible Colon Preparation

Information source: ColonaryConcepts LLC
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Bowel Preparation

Intervention: NuLYTELY® (PEG 3350) (Drug); ECP-019 (Drug); MoviPrep® (PEG 3350) (Drug)

Phase: Phase 2

Status: Recruiting

Sponsored by: ColonaryConcepts LLC

Official(s) and/or principal investigator(s):
Karl Gallegos, MD, Study Director, Affiliation: Not Affiliated

Overall contact:
Shelley Huneven, Phone: 603-504-2197, Email: info@colonaryconcepts.com

Summary

The purpose of this study is to learn about a new bowel preparation that uses food to clean the colon. In order to learn about this new food preparation, some people in this study will get the food preparation, and others will get the standard liquid bowel preparation. Patients will be randomized (like flipping a coin) to one of five groups:

Group 1 - Menu A Meal Kit - contains bars, shakes, soup, and a rice bowl Group 2 - Menu B

Meal Kit - contains bars, shakes, soup, and a rice bowl Group 3 - Menu C Meal Kit - contains

bars and shakes Group 4 - MoviPrep Group 5 - NuLYTELY

Clinical Details

Official title: An Adaptive, Single-Blind, Parallel, Randomized, Phase 2, Formulation Screening/Proof of Concept, Safety, Tolerability and Efficacy Study of Three Formulations/Dosing Regimens of ECP (PEG 3350) Colon Prep Kit Compared to Comparators.

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator)

Primary outcome: The proportion of patients with successful colon cleansing as assessed by the blinded gastroenterologists using the Aronchick Scale.

Secondary outcome: Percentage of patients who completed each of the ECP-019 formulation/dosing regimens

Detailed description: The purpose of this Phase 2 formulation screening/proof of concept study is to evaluate the safety, tolerability, and efficacy of up to 3 ECP-019 formulations/dosing regimens comprising a PEG 3350 Colon Prep Kit, containing electrolytes provided by the foods, in 3 formulations/ dosing regimens as compared to 2 comparators in a Phase 2 study.

Eligibility

Minimum age: 18 Years. Maximum age: 74 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Patients whose physician has prescribed colonoscopy for colorectal cancer screening

or surveillance for colorectal cancer.

- Patients with a previous history of completing a bowel cleansing procedure for a

colonoscopy.

- For women of child bearing potential, a negative pregnancy test.

- Patients who are willing and able to comply with study procedures.

- Documentation of informed consent by the use of a written consent form approved by

the IRB and signed and dated by the patient. Exclusion Criteria:

- Known intestinal stricture of any etiology.

- History of diabetes mellitus.

- Pregnancy.

- Patients with renal insufficiency defined as a Cr >2. 0 or a history of hypo- or

hyperkalemia, chronic liver disease, congestive heart failure, or arrhythmic disorder (i. e., higher risk of complications from electrolyte abnormalities than healthy patients).

- Patients being treated with warfarin, heparin (standard or low molecular weight

heparin) or clopidogrel, Pradaxa®, Xarelto®, Effient® or other anticoagulant agents.

- Previous history of inadequate preparation for a colonoscopy.

- Patients with a history of colonic resection, Crohn's disease, or ulcerative colitis.

- Severe psychological disease causing functional impairment limiting capacity to

complete the preparation.

- Use of narcotics/opiates within 2 weeks prior to the procedure.

- Use of anti-diarrheal within 2 weeks prior to the procedure.

- Use of drugs of abuse, including abused prescription medications.

- Use of iron oral supplements within 2 weeks of the procedure.

- Previous gastrointestinal surgery.

- A known diagnosis of gastroparesis.

- Symptoms of chronic constipation defined as fewer than three bowel movements per-week

on average over the previous 3 months.

- Clinically significant laboratory abnormalities as judged by the study investigator

from blood tests drawn at Screening study visit.

- Patients with any known allergies to the ingredients of the test products (aspartame,

gluten, lactose, milk, peanuts, sesame, soy, tree nuts, or wheat) or comparator products.

- Patients with phenylketonuria (PKU) or a known sensitivity to the artificial

sweetener called aspartame.

Locations and Contacts

Shelley Huneven, Phone: 603-504-2197, Email: info@colonaryconcepts.com

Indiana University, Indianapolis, Indiana 46290, United States; Recruiting
Douglas K. Rex, MD, Phone: 317-948-8741, Email: drex@iu.edu

Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire 03756, United States; Recruiting
Jessica I Chevalier, Phone: 603-653-9033, Email: Jessica.I.Chevalier@Hitchcock.org

Additional Information

Starting date: May 2015
Last updated: May 18, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017